🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “China” Clear

  1. Qizhi weitong granules(High）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Irritable Bowel Syndrome

    phase 2 small molecule active

    1 trial

  2. R-EPOCH in Combination With Ibrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Richter Transformation

    phase 2 small molecule active

    1 trial

  3. RC48- ADC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance

    phase 2 small molecule active

    1 trial

  4. RD14-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 mab active

    1 trial

  5. REGEND001 cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  6. Recombinant COVID-19 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  7. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  8. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  9. Recombinant Interferon Alpha

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Essential Thrombocytopenia

    phase 2 small molecule active

    2 trials

  10. Regorafenib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Regorafenib

    phase 2 small molecule active

    1 trial

  11. Remote ischemic preconditioning (RIPC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cerebrovascular Disease

    phase 2 other completed

    1 trial

  12. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial

  13. Rifaximin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Intestine Bacterial Overgrowth

    phase 2 small molecule active

    1 trial

  14. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Severe Aplastic Anemia

    phase 2 small molecule active

    1 trial

  15. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  16. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  17. Rituximab Paclitaxel Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  19. Romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule completed

    1 trial

  20. Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    aGVHD

    phase 2 small molecule completed

    1 trial

  21. Ruxolitinib 5 MG BID Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

    phase 2 small molecule active

    1 trial

  22. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  24. SG+I

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC, Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources